Qlucore AB

Qlucore is a life sciences software company founded in 2007, originating from a collaborative research project at Lund University, Sweden, between the Departments of Mathematics and Clinical Genetics. The company develops visualization-based analysis solutions designed to accelerate, simplify, and improve both research and cancer diagnostics. By leveraging the pattern-recognition power of the human brain through interactive 3D data visualization, Qlucore enables researchers, technicians, and physicians to explore, interpret, and act on complex multi-omics datasets with speed and confidence. Qlucore serves a broad audience spanning academic research institutions, clinical diagnostics laboratories, and pharmaceutical drug development teams pursuing precision medicine.

At the core of Qlucore's technology is a high-performance software engine capable of visualizing and analyzing high-dimensional data interactively and in real time on standard computers. The platform has evolved continuously since its founding, adding machine learning functionality in 2016, a Next Generation Sequencing (NGS) module with a dynamic genome browser in 2017, and expanding into precision and companion diagnostics in 2020. The company releases new versions of its flagship software approximately every nine months, ensuring users benefit from ongoing innovation.

Key Products

• Qlucore Omics Explorer (QOE): A powerful, flexible, and easy-to-use visualization tool for multi-omics data analysis. It supports fast exploration of high-dimensional datasets and is designed to require only a minimal number of key presses or mouse clicks to generate the first meaningful plot. The latest release, version 3.11, places special focus on proteomics and qPCR data analysis, reflecting the rapid expansion of proteomics in precision medicine and biomarker discovery. Users can also run custom R scripts for extended flexibility.
• Qlucore Insights: A disease-specific subtyping tool for research use, enabling scientists to classify and stratify samples by disease subtype to support deeper biological understanding and research advancement.
• Qlucore Diagnostics: An IVDR-certified, CE-marked diagnostic tool specifically developed for Acute Lymphoblastic Leukemia (BCP-ALL) in pediatric patients. This is the first CE-marked RNA-seq-based diagnostic test for pediatric leukemia under Europe's mandatory IVDR regulatory framework, now available for clinical delivery and use. It provides enhanced diagnostic accuracy and represents a significant milestone in the diagnosis of this common childhood cancer.

Core Capabilities

• Interactive, real-time 3D visualization of multi-omics data, enabling rapid identification of hidden patterns and structures in complex datasets
• Support for a wide range of data types including genomics, transcriptomics, proteomics, qPCR, and NGS data
• AI-powered, disease-specific machine learning-based classifier models integrated as plug-ins into a scalable and flexible platform
• Dynamic genome browser for NGS data analysis
• Real-time statistical analysis with interactive p-value cut-off adjustment
• Heatmap visualizations for uncovering hidden patterns and insights in data
• Report generation functionality built into the diagnostics platform
• Custom R script execution for advanced or bespoke analyses
• Disease subtyping capabilities, including early subtyping approaches that can reduce unclassified lung tumors by up to 80%

Platform and Deployment

• Available for both PC and Mac, with trial versions downloadable at no cost
• Designed for use on standard computers without requiring specialized hardware
• Scalable and flexible software platform built for precision oncology and future cancer detection and analysis models
• Supports companion diagnostics and precision diagnostics workflows, including patient-friendly visualizations and report generation
• Compliant with Europe's IVDR regulatory framework for in vitro diagnostic devices

Compliance and Standards

• Qlucore Diagnostics holds CE marking under the IVDR framework, the mandatory European regulatory standard for in vitro diagnostics
• The company is committed to the highest ethical standards and compliance with all applicable laws, rules, and regulations, as outlined in its Code of Conduct
• Sustainability is an integral part of Qlucore's operations and corporate values

Notable Customers and User Testimonials

• Researchers and scientists at leading institutions including Yale School of Medicine, Stanford University, and King's College London use Qlucore solutions
• Users highlight the platform's intuitiveness, enabling scientists to perform advanced bioinformatics analyses independently without requiring a biostatistician for every analytical step
• The software is praised for empowering non-computational scientists to rapidly explore and interpret omics data in real time

Qlucore was founded by a multidisciplinary team with a vision to unite research, diagnosis, and care in the pursuit of precision medicine. With a consistent track record of innovation and a growing portfolio of regulatory-compliant diagnostic tools, Qlucore continues to play a meaningful role in advancing precision oncology and enabling clinics and research institutions to implement the latest cancer detection and analysis capabilities.